stoxline Quote Chart Rank Option Currency Glossary
Aditxt, Inc. (ADTX)
1.985  -0.065 (-3.17%)    05-28 14:24
Open: 2.06
High: 2.06
Volume: 23,041
Pre. Close: 2.05
Low: 1.97
Market Cap: 4(M)
Technical analysis
2024-05-28 2:49:00 PM
Short term     
Mid term     
Targets 6-month :  2.8 1-year :  3.14
Resists First :  2.4 Second :  2.69
Pivot price 2.06
Supports First :  1.94 Second :  1.61
MAs MA(5) :  2.05 MA(20) :  2.13
MA(100) :  3.29 MA(250) :  9.36
MACD MACD :  -0.2 Signal :  -0.2
%K %D K(14,3) :  20.1 D(3) :  24.8
RSI RSI(14): 35.1
52-week High :  68.08 Low :  1.94
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ADTX ] has closed above bottom band by 9.7%. Bollinger Bands are 82% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 17 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.06 - 2.08 2.08 - 2.08
Low: 2 - 2.02 2.02 - 2.03
Close: 2.01 - 2.03 2.03 - 2.05
Company Description

Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.

Headline News

Fri, 03 May 2024
Aditxt, Inc. Merger with Evofem Biosciences Falls Through - - TipRanks

Thu, 04 Apr 2024
Aditxt, Inc. Announces Strategic Acquisition of Appili Therapeutics - - TipRanks

Tue, 02 Apr 2024
Aditxt to acquire Appili Therapeutics in strategic move -

Tue, 02 Apr 2024
Why Aditxt Stock Is Volatile Today - Aditxt (NASDAQ:ADTX) - Benzinga

Wed, 03 Jan 2024
Richmond's Aditxt reaches deal to acquire maker of Phexxi - The Business Journals

Mon, 01 Jan 2024
Evofem Acquired by Aditxt for $100M - San Diego Business Journal

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 2 (M)
Held by Insiders 1.66e+006 (%)
Held by Institutions 2.4 (%)
Shares Short 19 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -2.563e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -9 %
Return on Assets (ttm) 780 %
Return on Equity (ttm) -59 %
Qtrly Rev. Growth 645180 %
Gross Profit (p.s.) -51.1
Sales Per Share -277.11
EBITDA (p.s.) 0
Qtrly Earnings Growth -108.2 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -19 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 0.17
Stock Dividends
Dividend 0
Forward Dividend 165310
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android